Eledon Pharmaceuticals — Third Quarter 2026 Earnings Summary

Eledon Pharmaceuticals reported a net loss of $3.9 million for the third quarter of 2026, driven by $17.8 million in research and development expenses, while maintaining $69.7 million in cash and short-term investments sufficient to fund operations into the second quarter of 2027. The company received FDA Fast Track designation for tegoprubart in kidney transplantation and cleared an IND application for a registrational study in islet cell transplantation for type 1 diabetes. Clinical updates included new patient-reported outcome data showing improved quality of life and symptom burden for tegoprubart compared to tacrolimus in kidney transplant recipients, alongside long-term data demonstrating sustained eGFR advantages. Upcoming milestones include the initiation of the global Phase 3 LEGACY trial for kidney transplantation in the fourth quarter of 2026 and the start of a registrational path study for islet cell transplantation.